Brokers Set Expectations for MNPR Q1 Earnings

Key Points

• Brokline Capital Management forecasts Monopar Therapeutics will report a Q1 2026 loss of ($0.81) per share, maintaining negative earnings projections for the full year at ($1.65) per share.
• Several analysts have recently initiated coverage on Monopar, with multiple "buy" ratings and target prices ranging from $70.00 to $106.00.
• Insider sales are significant, with the CEO selling 16,800 shares and other insiders offloading over 592,733 shares in the last 90 days, indicating a potential lack of confidence in the company's stock performance.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Investment analysts at Brookline Capital Management issued their Q1 2026 earnings per share estimates for Monopar Therapeutics in a research note issued to investors on Thursday, September 25th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn ($0.81) per share for the quarter. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. Brookline Capital Management also issued estimates for Monopar Therapeutics' Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.82) EPS and Q4 2026 earnings at ($0.83) EPS.

Several other analysts have also issued reports on MNPR. Lake Street Capital started coverage on Monopar Therapeutics in a research note on Tuesday, September 23rd. They issued a "buy" rating and a $106.00 target price for the company. BTIG Research increased their price objective on Monopar Therapeutics from $87.00 to $104.00 and gave the company a "buy" rating in a research note on Thursday. Chardan Capital increased their price objective on Monopar Therapeutics from $60.00 to $85.00 and gave the company a "buy" rating in a research note on Thursday. HC Wainwright started coverage on Monopar Therapeutics in a research note on Tuesday, August 26th. They set a "buy" rating and a $70.00 price objective for the company. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Monopar Therapeutics in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Monopar Therapeutics currently has an average rating of "Buy" and a consensus target price of $82.33.

Monopar Therapeutics Price Performance

Shares of MNPR opened at $76.63 on Monday. The firm has a market cap of $472.81 million, a P/E ratio of -23.01 and a beta of 1.20. The stock has a 50 day simple moving average of $44.46 and a two-hundred day simple moving average of $39.50. Monopar Therapeutics has a 1 year low of $4.50 and a 1 year high of $79.80.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.12.

Insiders Place Their Bets

In related news, CEO Chandler Robinson sold 16,800 shares of the company's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the transaction, the chief executive officer owned 73,472 shares in the company, valued at $2,938,880. This represents a 18.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the company's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $356,160.00. Following the transaction, the director owned 11,486 shares of the company's stock, valued at approximately $459,440. This represents a 43.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 592,733 shares of company stock worth $36,700,227 in the last ninety days. Insiders own 20.50% of the company's stock.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Monopar Therapeutics during the 2nd quarter valued at $34,000. AlphaQuest LLC purchased a new position in Monopar Therapeutics during the 1st quarter valued at about $44,000. JPMorgan Chase & Co. lifted its position in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock valued at $69,000 after acquiring an additional 1,821 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Monopar Therapeutics during the second quarter worth about $80,000. Finally, New York State Common Retirement Fund purchased a new stake in Monopar Therapeutics in the second quarter worth about $104,000. Hedge funds and other institutional investors own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.